RecruitingPhase 1Phase 2NCT07800871

FT839 in Autoimmune Diseases

An Open-Label, Multicenter, Phase 1/2 Dose-Escalation and Expansion Trial Evaluating the Safety and Efficacy of FT839 in Participants With Autoimmune Diseases

Sponsor

Fate Therapeutics

Enrollment

446 participants

Start Date

Oct 1, 2026

Study Type

INTERVENTIONAL

Conditions

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)ANCA Associated Vasculitis (AAV)Idiopathic Inflammatory Myositis (IIM)

Summary

The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called FT839 for people with anca associated vasculitis (aav), idiopathic inflammatory myositis (iim), and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALFT839

Single Intravenous (IV) infusion of FT839 administered on Day 1 and Day 4

Locations(1)

Providence Medical Foundation

Fullerton, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07800871

Related Trials

Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis

NCT07746180

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

NCT0733248113 locations

A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic Diseases

NCT066470697 locations

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

NCT068759604 locations

Effect of Lavender Aromatherapy Massage on Pain and Wrist Mobility in Rheumatoid Arthritis

NCT07456657